- Home
- MLNK vs TARS Comparison
MLNK vs TARS Comparison
Compare MLNK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- TARS
- Stock Information
- Founded
- MLNK 1998
- TARS 2016
- Country
- MLNK United States
- TARS United States
- Employees
- MLNK N/A
- TARS N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- TARS Medicinal Chemicals and Botanical Products
- Sector
- MLNK Technology
- TARS Health Care
- Exchange
- MLNK Nasdaq
- TARS Nasdaq
- Market Cap
- MLNK 1.5B
- TARS 1.7B
- IPO Year
- MLNK 2021
- TARS 2020
- Fundamental
- Price
- MLNK $19.98
- TARS $53.53
- Analyst Decision
- MLNK Hold
- TARS Strong Buy
- Analyst Count
- MLNK 8
- TARS 7
- Target Price
- MLNK $21.21
- TARS $67.14
- AVG Volume (30 Days)
- MLNK 357.8K
- TARS 679.4K
- Earning Date
- MLNK 11-06-2025
- TARS 11-12-2025
- Dividend Yield
- MLNK N/A
- TARS N/A
- EPS Growth
- MLNK N/A
- TARS N/A
- EPS
- MLNK N/A
- TARS N/A
- Revenue
- MLNK $325,891,000.00
- TARS $295,521,000.00
- Revenue This Year
- MLNK $6.47
- TARS $33,170.29
- Revenue Next Year
- MLNK $5.54
- TARS N/A
- P/E Ratio
- MLNK N/A
- TARS N/A
- Revenue Growth
- MLNK 5.96
- TARS 254.45
- 52 Week Low
- MLNK $15.49
- TARS $30.23
- 52 Week High
- MLNK $25.33
- TARS $59.76
- Technical
- Relative Strength Index (RSI)
- MLNK 71.77
- TARS 52.59
- Support Level
- MLNK $19.85
- TARS $48.20
- Resistance Level
- MLNK $19.98
- TARS $59.76
- Average True Range (ATR)
- MLNK 0.08
- TARS 2.12
- MACD
- MLNK -0.11
- TARS -1.02
- Stochastic Oscillator
- MLNK 78.26
- TARS 46.28
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.